Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Chia-tai Tianqing Pharma Gains China Rights for Hepatitis C Drug from BioLineRx

publication date: Jun 10, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Jiangsu Chia-tai Tianqing Pharmaceutical Co. in-licensed China rights to BL-8030, an oral treatment for hepatitis C virus, from BioLineRx, an Israeli clinical-stage pharma. CTTQ makes chemical drugs and TCM products, with liver disease a specialty for the company. BioLine will be eligible for up to $30 million in upfront and milestone payments. More details....

Stock Symbol: (NSDQ: BLRX); TASE: BLRX)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...